Repligen, a global life sciences company, develops and commercializes innovative bioprocessing technologies that increase efficiencies and flexibility in biotherapeutic manufacturing. As leaders in filtration, chromatography systems, process analytics and fluid management, we are committed to inspiring advances in bioprocessing. We are a trusted partner in the production of monoclonal antibodies, recombinant proteins, vaccines as well as cell and gene therapies. Named one of the fastest growing biotech companies in the USA, the majority of our 18 manufacturing sites are located in the United States (California, Massachusetts, New Jersey, New Hampshire, New York and Texas). Outside the United States, we have manufacturing sites in Estonia, France, Germany, Ireland, the Netherlands, and Sweden. | Repligen, a global, bioprocessing-focused life sciences company, provides innovative solutions for the advancement of biotherapeutic manufacturing. Experts in filtration, chromatography systems, process analytics, fluid management, and proteins, Repligen is a trusted partner serving the development and manufacture of a wide range of biologics, including cell and gene therapies, mRNA, monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), bispecific antibodies, and fusion proteins. Headquartered in Waltham, Massachusetts, USA, Repligen operates across 22 sites, including locations in the United States, Europe, and the Asia-Pacific region. | Inspiring advances in bioprocessing, Repligen is a trusted partner in process intensification, pre-packed chromatography and single-use filtration. Focused on cost and process efficiencies, our people and our technologies help meet critical bioproduction demands worldwide. As the recognized global leader in Protein A manufacturing, Repligen’s Protein A affinity ligands are routinely used to purify most of the world’s monoclonal antibodies.
Phastar
Phastar is an award-winning biometrics and data science CRO, trusted by pharma, biotech, and medical device companies worldwide. With a global team of data specialists, we bring expertise, precision, and pace to every trial—because behind every data point is a patient waiting for treatment. We don’t just deliver on-time high quality data; we partner with you to turn complexity into clarity. Leveraging best-in-class technology, AI-enhanced analytics, advanced statistical methods, and deep therapeutic expertise, we accelerate regulatory approvals, ensure compliance with global standards and seamlessly mitigate risk. Our proven track record in transforming complex data into clear, actionable intelligence enables you to accelerate drug development. With scalable, tailored solutions, we expedite trials—bringing life-changing therapies to patients faster.
Owkin
Owkin is an Agentic AI company pioneering the use of data, biology, and AI to decode the fundamental mechanics of disease and advance medical science. By focusing on the system’s ability to uncover biology’s ground truth at scale, Owkin aims to revolutionize the way we diagnose and treat diseases. With a vision of achieving a “positive singularity” in medicine, Owkin leverages AI to deliver transformative therapies at an exponential scale, addressing the complexities of biology that traditional pharmaceutical approaches often cannot solve. Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across nine cancer indications. Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like F-Prime, GV and Bpifrance, among others.
NEUROPHET
NEUROPHET Inc., Seoul, Republic of Korea, with expertise in neuroscience. We have been focusing on developing and providing innovative medical solutions for helping patients suffering from neurological diseases. To achieve the mission, we have applied state-of-the-art AI technologies to our expertise in neuroimaging, brain modeling and neuromodulation. We are conducting research in imaging-based biomarkers for Alzheimer’s disease (AD), which will be valuable tool for clinical trials (surrogate biomarker for drug response and disease progression) and companion diagnostics for AD therapeutics and furthermore, global standardization for AD staging and diagnostics. Neurophet provides medical-grade solutions approved by international regulatory bodies. | Neurophet Inc. develops advanced AI-powered neuroimaging solutions to enhance the diagnosis, monitoring, and treatment planning of neurological disorders. Its flagship products—AQUA AD, AQUA, and SCALE PET—deliver precise, quantitative insights into brain atrophy, lesion dynamics, and imaging biomarkers, including those associated with amyloid-targeted therapeutics (ATT) and amyloid-related imaging abnormalities (ARIA), through MRI and PET imaging. | Neurophet is a specialized company developing AI-powered brain imaging analysis solutions and therapeutic medical devices, covering the full cycle of neurological care — from MRI and PET analysis to wearable brain stimulation devices. We support medical institutions with AI-based imaging for diagnosis and treatment monitoring, and provide standardized central imaging services for global pharmaceutical clinical trials through our Imaging Core Lab (ICL). From the clinical frontline to global clinical trials, Neurophet is advancing as a global leader in neurological imaging analysis.
iRepertoire
Over the past decade, iRepertoire has developed gold standard technologies for immune repertoire sequencing. Our core technologies provide the ability to amplify expressed V(D)Js in B or T cells, and we offer the only technology that can measure all 7 immune chains simultaneously. We also offer a single cell solution to capture V(D)J rearrangements from rare cell populations. Beyond sequencing, iRepertoire now provides comprehensive data analysis services that accelerate biomarker discovery, advance disease research, and support IO drug development programs. iRepertoire is committed to creating cutting-edge technology and analytical solutions that adapt to the ever-changing immune sequencing landscape. | .
Insilico Medicine
We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry, and clinical development. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients while decreasing costs and increasing probabilities of success. | Insilico Medicine is a leading generative AI-driven biotech company. Our mission is to accelerate drug discovery and development by leveraging our robust Pharma.AI platform across biology, chemistry and clinical development. With 31 programs in development including 5 clinical stage assets, our generative AI platform helps us advance the pipeline of novel drug candidates rapidly and effectively in oncology, immunology, anemia, fibrosis, COVID and others. We are actively looking for asset out-licensing and strategic biopharma partners to develop successful drugs together to help patients. In addition we have a suite of AI software tools that can be licensed for drug discovery. | We are a globally leading end-to-end generative AI-driven biotech company in terms of AIDD pipeline progress, with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary Pharma.AI platform across biology, chemistry and clinical development. Our generative AI platform helps us to rapidly and efficiently advance our fully self-generated AIDD pipeline primarily composed of novel drug candidates.
iLoF
iLoF is a digital health company pioneering a breakthrough AI-platform to accelerate the future of personalized drug discovery and development. Through advanced AI and Photonics, iLoF is collecting massive amounts of data to build a digital library of biomarkers and biological profiles, bringing together world-class physicists, biologists, and data scientists to get life-saving personalized treatments to patients faster. Recognized by CB Insights as one of the top Digital Health companies in the world and by the Financial Times as a Transformational Business in Healthcare, iLoF is supported by leading institutions like Microsoft Ventures, Mayfield or the Oxford University, and has been regularly featured by outlets like Tech Crunch, Wired, or Sifted as a rising star in AI-Driven Drug Discovery, Health Screening & Data Analytics.